Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
about
Epigenetic changes of DNA repair genes in cancerGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyFancf-deficient mice are prone to develop ovarian tumoursPromoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian CancerMolecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.DNA methyltransferases, DNA damage repair, and cancerDiffering clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cellsGenetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.Translational application of epigenetic alterations: ovarian cancer as a model.RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.Pharmaco(epi)genomics in ovarian cancer.BRCA and Early Events in the Development of Serous Ovarian Cancer.RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.Fanconi anaemia: from a monogenic disease to sporadic cancer.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.
P2860
Q22242858-1C1CFF76-53E9-4088-B5BB-7099AE76C6F4Q26769604-DE913214-FB1F-4BBD-B2F4-0D7C1A59C291Q28247935-428D0412-6C6D-42CD-A621-F0546500DEECQ28269159-38CBAC34-684E-42DE-9B5C-B449E95D8D71Q30448232-32D39C68-BC9C-4505-8FBD-1BA2CC64FF72Q34298096-B717A3BC-9B9C-4DFA-88D7-B379CD13A685Q34305493-CB10AEF5-CE2B-469F-9442-230378F01755Q34406515-1CDC0111-DB22-412F-A669-09527FBD06C9Q34899498-C15E5A7B-3CB7-4B9B-A5F3-92AF7ABFFAC3Q35085782-F0464CD7-478C-4781-AB73-0708E500359BQ36858599-438504D3-2BA6-4494-9159-ABAE05BCFBDCQ37346198-09827C6A-BD4D-4A2D-9E00-636BE42B941FQ37513137-11697FCF-8F15-4803-B82A-9BC6AD8B7942Q37600026-B79E2618-6D2D-4F65-870B-EE1855C1C9B2Q37865169-7E01280A-6518-43A4-9774-9E5DB8FAFB03Q37933098-7356D959-D2D3-4108-96AC-12D6B8E40EA4Q38699009-4A4DF7DE-0DBF-48F2-80D3-0C8A5E078C48Q42378380-E90E47CD-DBE8-4435-AD76-640EE6DAF848Q42461070-AD10DE55-5E1D-4437-9E49-647EF0043696Q49833942-380659A6-C5DF-4F41-AE3D-6AE1081155A0Q51800946-6D930260-E0B3-4CE9-AD21-E6C27A06C7AD
P2860
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@ast
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@en
type
label
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@ast
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@en
prefLabel
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@ast
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@en
P2093
P2860
P356
P1476
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
@en
P2093
M van der Burg
P Szlosarek
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604325
P407
P577
2008-04-15T00:00:00Z